ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / BNGO / insiders
ASTC (28) EYPT (26) PRPO (30) RPID (34) ⌘ Pro Terminal β†’

Bionano Genomics Inc. (BNGO) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.16 +0.87% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.16

Bionano Genomics Inc. (BNGO) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $16.1M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BNGO Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is BNGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Bionano Genomics Inc. (NASDAQ: BNGO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.16 (+0.87% 1D, market cap $16.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BNGO ranks #845 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does BNGO compare to ASTC and EYPT in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), BNGO carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 46.3%, and ROIC of -35.0%. By comparison, ASTC (Astrotech Corporation) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $10.2M) and EYPT (EyePoint Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, BNGO leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BNGO?
β–Ό

Per BNGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001411690), Bionano Genomics Inc. generated $28.5M in revenue (-7.4% YoY), -$26.4M in net income, and -$16.3M in free cash flow against $73.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.16 (-0.03%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (29/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510029
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (7)Whales (3)SEC (8)Macro (6)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-12.9% Base Target
$2 Bull$1 Base$1 Bear
πŸ“¬ FREE BNGO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for BNGO)Realized 20D OHLCV Swing Band: Β±12%
Deterministic 5-Pillar Attribution (29/100 Composite)
πŸ” WHY BNGO SCORES 29/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 4/9

β–² #2 Bullish Driver: Cash Engine Quality+7/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 46.3% Gross Margin

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
37
Grade E$1.36-8.1% Next Q
Q2 (-2Q)
34
Grade E$1.25-2.4% Next Q
Q3 (-1Q)
32
Grade E$1.22-4.9% Next Q
Current
29
Grade E$1.16-9.8% Hist 90D Ξ±
Trajectory: E (37) β†’ E (29)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a BNGO Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While BNGO currently carries a cautious 29/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.37) and Max Pain ($1.22) forces dealer call-delta covering toward $2.34.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BNGOβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œBNGO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

BNGO Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BNGO)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BNGO. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BNGO)

  • βœ“Walkthrough of BNGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
BNGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.45%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $1.20H $1.20L $1.15C $1.16VOL 196.5K
RES: $2.57SUP: $1.09SMA50: $1.37SMA200: $1.24
$2.32$1.96$1.60$1.25$0.89RES $2.57SUP $1.09$1.162026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BNGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ BNGO Butterfly Map β†’ + Track BNGO β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -7.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BNGO today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for BNGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BNGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BNGO)

Health Care Rank #845 of 1015 βš”οΈ ASTC vs BNGO Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (BNGO vs. ASTC, EYPT, PRPO, RPID)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Bionano Genomics Inc. (BNGO) ranks #845 by composite RQD confidence (29/100, grade E) and #847 by equity capitalization ($16.1M). Within this direct 5-issuer industry benchmark cohort, BNGO leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. RPID currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with BNGO at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BNGO ACTIVE
Bionano Genomics Inc.
E 29/100 β€” 46.3% -35.0% +0.87% $16.1M Benchmark Subject
ASTC
Astrotech Corporation
E 28/100 β€” 47.5% -35.0% -2.69% $10.2M /astc-vs-bngo β†’
EYPT
EyePoint Inc.
E 26/100 β€” β€” -35.0% +7.58% $30.0M /eypt-vs-bngo β†’
PRPO
Precipio Inc.
E 30/100 β€” 44.2% -7.9% -1.71% $32.4M /prpo-vs-bngo β†’
RPID
Rapid Micro Biosystems Inc. (Class A)
E 34/100 β€” β€” -35.0% -4.50% $36.9M /rpid-vs-bngo β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001411690 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bionano Genomics Inc. (BNGO) reported GAAP revenue of $28.5M (-7.4% vs. FY2024 revenue of $30.8M , and -21.1% cumulative change since FY2023) , GAAP net income of -$26.4M, operating cash flow of -$16.3M, and free cash flow of -$16.3M (+76.3% YoY). On the balance sheet, BNGO closed FY2025 with $73.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $28.5M -$26.4M -$16.3M -$16.3M $73.6M β€”
FY2024 (FY) 2024-12-31 $30.8M -$112.0M -$68.9M -$68.9M $76.7M β€”
FY2023 (FY) 2023-12-31 $36.1M -$232.5M -$125.2M -$125.2M β€” β€”

3. BNGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BNGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Bionano Genomics Inc. (NASDAQ: BNGO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.16 (+0.87% 1D, market cap $16.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BNGO ranks #845 in composite RQD confidence.

How does BNGO compare to ASTC and EYPT in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), BNGO carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 46.3%, and ROIC of -35.0%. By comparison, ASTC (Astrotech Corporation) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $10.2M) and EYPT (EyePoint Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, BNGO leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BNGO?

Per BNGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001411690), Bionano Genomics Inc. generated $28.5M in revenue (-7.4% YoY), -$26.4M in net income, and -$16.3M in free cash flow against $73.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BNGO trading relative to its 50-day, 200-day, and 52-week technical levels?

BNGO last traded at $1.16 (+0.87% on volume of 89,153 shares), positioning the stock -15.33% below its 50-day simple moving average ($1.37) and -6.45% below its 200-day simple moving average ($1.24). Across its 52-week range of $1.00 to $2.23, BNGO sits at the 13.0% percentile with a 14-day RSI of 36.8 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.0% ($1.02 to $1.30).

Direct Sub-Reports: BNGO RQD Cockpit BNGO 12M Forecast BNGO Earnings & Move BNGO Dividends & DRIP BNGO Insiders & 13F BNGO Whale Options BNGO Profit Sankey BNGO News & Why
ROARABLE RATING BRIEF β€’ RQD 29/100 (E) βœ“ SEC XBRL & RQD VERIFIED

BNGO β€” Bionano Genomics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Bionano Genomics Inc. (BNGO) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.16 (+0.87% 1D, market capitalization $16.1M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 46.3%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Bionano Genomics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Laboratory Analytical Instruments. Its market capitalization is $0.0B. The reported gross margin of 46.3% indicates the company retains a portion of revenue after direct costs.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Bionano Genomics Inc. (BNGO) reported $28.5M in annual revenue (up from $30.8M in FY2024, -7.4% YoY) and -$26.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($36.1M revenue, -$232.5M net income) through FY2025, BNGO scaled operating cash flow to -$16.3M and free cash flow to -$16.3M, backed by $73.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.00 – $2.23 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The one investor-relevant ripple the sources do surface is financing-related: the shelf filing and offering amendment alongside the near-term capital need point to the possibility that capital-raising activity could affect the share count, a mechanism worth monitoring around the Nov 10 results webcast.

  • Key Question #1: Can BNGO sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $28.5M and free cash flow of -$16.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BNGO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BNGO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Bionano Genomics Inc. (BNGO) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to BNGO Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BNGO Bull vs. Bear Conversation Board β€” What's Your Call at $1.16?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BNGO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BNGO:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER β€’ Growth & Tech Investor πŸ‚ BULLISH 🎯 Target: $1.46 (+27.0%)
πŸ“Œ Pinned Debate

Revenue has held in the high-$20M range across FY 2023 to FY 2025 while operating losses narrowed from -$215.2M to -$33.3M, with a 46.3

Revenue has held in the high-$20M range across FY 2023 to FY 2025 while operating losses narrowed from -$215.2M to -$33.3M, with a 46.3% gross margin.. When you look under the hood at BNGO, Fundamental Cash Engine is 7/20 with 46.3% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $2.23. My 12M target is $1.46.

VolSurface_Trader πŸ‚ BULL

@RedlineAuditor Shorting a 3/20 institutional whale-flow stock at $1.15 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER β€’ Accounting Quality Watch 🐻 BEARISH 🎯 Target: $0.91 (-20.9%)
Spot @ $1.15

With $3.0M of cash, a negative FCF of -$16.3M, a stated near-term capital need, and a $400M mixed shelf, the company faces significant

With $3.0M of cash, a negative FCF of -$16.3M, a stated near-term capital need, and a $400M mixed shelf, the company faces significant dilution and financing risk.. Look at the math on BNGO: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Laboratory Analytical Instruments demand softens. I'd wait for a retest of $1.01 before getting long.

LIVE TAPE